Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade

Amgen (AMGN) shares recently declined 5.84%, significantly underperforming the broader market's gains, despite prior outperformance against its sector. Investors await the biotech giant's upcoming financial results, which are projected to show a 4.83% increase in quarterly EPS to $5.21 and 5.59% revenue growth to $8.86 billion. While AMGN trades at a forward P/E of 13.9, a discount to its industry's 19.6, its PEG ratio of 2.62 is above the industry average of 1.36, presenting a mixed valuation despite a recent slight positive revision to analyst EPS estimates.

Analysis

Amgen experienced a significant single-day stock decline of 5.84% to $272.44, starkly underperforming the broader market's gains and reversing its recent outperformance where it had gained 6.5%. This sharp price movement precedes the company's upcoming earnings release, which will be closely watched. Consensus estimates project solid year-over-year growth, with quarterly revenue expected to rise 5.59% to $8.86 billion and EPS to increase 4.83% to $5.21. Full-year forecasts are similarly positive, anticipating revenue and EPS growth of 5.36% and 4.94% respectively, supported by a minor 0.16% upward revision in consensus EPS estimates over the past month. Despite these positive fundamentals, valuation metrics present a mixed picture. The stock trades at a discounted Forward P/E of 13.9 versus its industry's 19.6, suggesting value. However, its high PEG ratio of 2.62, substantially above the industry average of 1.36, implies its price may not be justified by its expected earnings growth rate. This combination of factors is reflected in its neutral Zacks Rank of #3 (Hold).

Key Decisions for Investors

• Investors should scrutinize the conflicting valuation signals, where the stock's discounted forward P/E of 13.9 is offset by a high PEG ratio of 2.62, indicating potential overvaluation relative to its expected growth rate.
• The upcoming earnings report is a critical catalyst; its results and management guidance will be key to understanding the driver behind the recent 5.84% share price decline and will likely determine the stock's near-term trajectory.
• Given the recent share price weakness despite positive earnings forecasts and a neutral 'Hold' rating from Zacks, a cautious approach is warranted until the company provides updated guidance in its next financial report.